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Sir,  
 
A 43-year-old female presented to the emergency department because of 
dizziness, drowsiness and generalized urticaria that occurred the day prior. 
Patient’s history revealed protracted delivery with neonate asphyxia, following 
which she had been diagnosed with epilepsy at age seven when she experienced 
her first generalized tonic-clonic seizure. Her MRI showed ulegyria and hypoxic-
ischaemic changes characteristic for perinatal damage. Her last visit to an 
epilepsy clinic was eighteen days before. At that time a change in her therapy 
was made with gradual initiation of oxcarbazepine (start dose of 300 mg QD in 
the evening for 5 days, than 300 mg BID for 5 days, than 300 mg in the morning 
and 600 mg in the evening for 5 days) and tapering of levetiracetame. Her 
therapy, at the time of her presentation to the emergency department, was (in 
total daily doses): oxcarbazepine 900 mg, sodium valproate 1000 mg, 
levetiracetame 750 mg, clonazepam 4.5 mg, lamotrigine 100 mg. Neurologic 
examination revealed a jerky see-saw nystagmus (SSN) more pronounced on the 
right eye (Video 1). Brain CT scan was normal. Oxcarbazepine and lamotrigine 
were discontinued and carbamazepine was gradually introduced. The 
carbamazepine was chosen because this drug controlled her seizures very well 
in the past, however pediatric neurologist chose to switch from carbamazepine 
to levetiracetame at one point.  On follow-up, a week later, she didn’t have 
nystagmus and didn’t experience dizziness and drowsiness any more but still 
had residual urticaria on her face and neck.  
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SSN is a torsional-vertical nystagmus in which one eye elevates and intorts, while 
the other depresses and extorts. Jerky SSN is reportedly caused by lesions in the 
chiasmal or parasellar area thus resulting from disruption of the visual pathway 
(1). However, SSN was described in association with vascular and inflammatory 
lesions of the rostral midbrain, pons and cerebellum (1, 2). Based on these 
reports, SSN can result from dysfunction of the medial longitudinal fasciculus 
(MLF) that coordinates input to the oculomotor and trochlear nuclei from the 
vestibular nuclei (2).  
One of the most common side-effects of oxcarbazepine therapy is nystagmus and 
it is related to its mono-hydroxy-derivative levels in serum (3). The therapeutic 
effect of oxcarbazepine results from its effect of blocking neural ion channels. We 
hypothesize that that same effect caused SSN in our patient blocking neurons 
that are part of the MLF. As nystagmus is a well described side-effect of 
antiepileptic therapy and given the fact that nystagmus in our patient 
commenced on initiation and disappeared on discontinuation of oxcarbazepine, 
we report on a yet undescribed case of jerky SSN caused by oxcarbazepine. 
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Video 1. Jerky see-saw nystagmus (SSN) more pronounced on the right eye. 
